Pharma Condition Briefs  ·  Patient and prescriber audiences, scored for fit and measured weekly  ·  audience@semcasting.com

Cardiometabolic

Type 2 Diabetes Patient and Prescriber Audiences

ICD-10E11

In our Audience Quality Test, the type 2 diabetes audience held 1.65× more high-fit households than the U.S. population, and 1.66× more qualified households. Brands can reach patients and the prescribers who treat them, with results reported every week. At $1.50 to $3.00 CPM, these audiences are priced at approximately 50% or less of the market rate.

Qualified audience

Every household and prescriber is scored 0 to 100 for fit to this condition. You buy only the tiers that qualify.

$1.50 to $3.00 CPM

Priced at approximately 50% or less of the market rate for pharma audiences.

Weekly measurement

Qualified reach, lift against the national baseline, and reach by state, reported every week.

Patients · DTC validated

Households in test audience
7.4M
High-fit people, national (score 67+)
19.1M
Qualified people, national (score 63+)
55.2M
Digitally active, qualified
20.1M
Test audience
12.5%
U.S. population
7.6%

Share of households clearing the high-fit bar (score 67+). Qualified tier (score 63+): 36.3% in the test audience vs 21.9% nationally.

Prescribers · HCP active Type 1 NPIs

SpecialtyNPIsAt home
Treating339,687208,401
Endocrinology12,5527,565
Family & internal medicine327,135200,836
Referring426,779257,341
Primary care nurse practitioners378,848225,682
Cardiology34,27922,931
Nephrology13,6528,728
Total prescribers766,466465,742

Counted by primary NUCC taxonomy in the CMS NPPES registry (September 2026). "At home" means matched to a home address in Semcasting's NPI file, for reach on CTV, streaming and display. Referring counts exclude doctors already counted as treating.

Where qualified patients concentrate top states by share

  1. Louisiana
  2. Georgia
  3. Mississippi
  4. Alabama
  5. South Carolina
  6. Texas

Common questions

How many prescribers treat type 2 diabetes?

339,687 active Type 1 NPIs in the treating specialties (endocrinology and family & internal medicine), 208,401 of them matched to a home address for CTV, streaming and display. Another 426,779 referring prescribers are counted separately. Counts come from the CMS NPPES registry, September 2026.

How was the type 2 diabetes patient audience validated?

In Semcasting's Audience Quality Test, the type 2 diabetes audience held 1.65x more high-fit households than the U.S. population (score 67 or higher) and 1.66x more qualified households (score 63 or higher). During a campaign the same comparison runs every week on the households actually reached.

Does the type 2 diabetes audience use diagnosis, claims or prescription data?

No. Patient audiences are built from peer-reviewed, population-level public health reporting and population surveys, scored against Semcasting's national adult file. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.

Evidence base primary sources for type 2 diabetes

  • Federal public healthCDC National Diabetes Statistics Report
  • Disease associationAmerican Diabetes Association
  • Population surveyCDC PLACES: Diabetes (state and county)

How the audience is built

Patient counts for type 2 diabetes come from physician-reported registries, diagnostic population surveys, and federal (CDC, CMS, NIH) and disease-association reporting, listed above. Each of 251.7M U.S. adult records is scored 0 to 100 for fit to those published patient profiles by age, gender and income, weighted by geographic prevalence (CDC PLACES: Diabetes (DIABETES)). Qualified means a score of 63 or higher. High-fit means 67 or higher.

How quality is confirmed

Audience quality has historically been confirmed through holdout sampling: a delivered audience is compared with the full national panel at the same fixed score cutoffs, and the difference is reported as lift. During a campaign, the same comparison runs every week on the households actually reached.

What it is not

Qualified audiences are not built from modeled claims data extrapolated from a few locations. They come from peer-reviewed, population-level public health reporting on patient profiles and population surveys. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.